Business Wire

Bertin and Zymo Research Announce New Collaboration

Del

Zymo Research Corp. and Bertin announce a collaboration that ensures the sample lysis step in the microbiome workflow is complete and unbiased. An application note is available describing the materials, procedure and results attained using the Precellys® Evolution Homogenizer together with the ZymoBIOMICS® Microbial Community Standards and ZymoBIOMICS DNA Miniprep Kit for purification of the DNA. Using both companies’ products, the researcher is afforded unbiased cell lysis in only one minute. The application note validates a procedure for accurate downstream microbiome measurements.

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171207005711/en/

Picture showing the Precellys® & Cryolys Evolution tissue homogenizer equipment on the bench - Credi ...

Picture showing the Precellys® & Cryolys Evolution tissue homogenizer equipment on the bench - Credit: T.Leaud

Zymo Research’s suite of ZymoBIOMICS® products addresses the complete Microbiomics workflow; from sample collection, DNA extraction, library prep, sequencing, through bioinformatics and final analysis. The ZymoBIOMICS® Microbial Community Standard contains three easy-to-lyse Gram-negative bacteria, five tough-to-lyse Gram-positive bacteria, and two tough-to-lyse yeasts. These accurately characterized microbial standards, enable the identification of exposure to artifacts, errors, and bias in microbiomics or metagenomics workflows, specifically 16S rRNA and shotgun-based sequencing approaches. Used in conjunction with the microbial standards, Zymo Research offers low-bioburden DNA isolation kits tuned for complete lysis of microbes with an innovative bead and buffer system.

Bertin has been in the sample preparation and homogenization instrumentation market for over ten years. Their line of Precellys homogenizers have won widespread recognition from the scientific community as hard-wearing, efficient and ergonomic research tools and have been cited widely in the literature. Initially designed for BSL-3 (Biological Safety Level) laboratories, the Precellys® Evolution makes it possible to efficiently homogenize a number of samples using an assortment of different-sized tubes, from 0.5 ml to 15 ml and it guarantees identical homogenization in each of the tube positions.

Bead beating is an accepted method to lyse various microbes but until now we have not been able to accurately assess the efficiency of the lysis. ”With the combination of Bertin’s homogenizer and Zymo Research’s Microbial Community Standard and DNA Miniprep Kit researchers and clinicians now have a rapid, complete homogenization procedure at their disposal ” said Marc Van Eden, Vice-President of Business Development at Zymo Research Corp.

www.bertin-instruments.com
www.zymoresearch.com

Contact information

BERTIN :
Gootenberg agency
Laurence Colin, Tel : +33 (0)1 43 59 00 46
laurence.colin@gootenberg.fr
or
ZYMO RESEARCH CORP.:
KIWI Communications, Inc.
Sheila T. Brann, Tel: +714.979.3464
sbrann@kiwi-comm.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

AURAK Gains SACSCOC Accreditation15.12.2018 10:49Pressemelding

The Southern Association of Colleges and Schools Commission on Colleges (SACSCOC) officially announced the accreditation of the American University of Ras Al Khaimah (AURAK) at its 2018 Annual Meeting which was held in New Orleans, Louisiana, in the United States of America. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181215005017/en/ AURAK delegation during the SACSCOC conference in New Orleans” (Photo: AETOSWire) SACSCOC, the regional body for the accreditation of degree-granting higher education institutions in the Southern United States, has a membership of more than 800 institutions in the Southern states and other international sites approved by SACSCOC that award associate, baccalaureate, master’s, and/or doctoral degrees. SACSCOC also awards accreditation to other international institutions of higher education that satisfy all its requirements and demonstrate compliance with its accreditation standards. AURAK now

Lehman Brothers Treasury Announces Plans for Partial Wind-Down14.12.2018 17:41Pressemelding

Lehman Brothers Treasury Co. B.V. in liquidation (“LBT”) today, through its U.S. counsel Kramer Levin Naftalis & Frankel LLP, announced that LBT is planning a final cash distribution to its creditors. Professional holders of eligible notes will have the option to retain their investment by electing to receive substitute notes of one (or a few) series. Such election shall take place through a solicitation process. As a consequence, LBT will be able to reduce the number of series of notes outstanding from more than 3,700 to one or a few. Noteholders electing to receive substitute notes will be afforded the same economic entitlement to distributions received by LBT from Lehman Brothers Holdings Inc. (“LBHI”) through the substitute notes. The substitute notes will be denominated in U.S. dollars and future distributions will be made in U.S. dollars only. Noteholders who are not professional investors, or hold notes that are not eligible for substitution, or do not elect to receive substitut

Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma in Combination with AVD14.12.2018 17:00Pressemelding

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the extension of the marketing authorization of ADCETRIS (brentuximab vedotin) and recommended its approval in combination with AVD in adult patients with previously untreated CD30+ Stage IV Hodgkin lymphoma. ADCETRIS is an antibody-drug conjugate (ADC) directed at CD30, a defining marker of Hodgkin lymphoma. ADCETRIS is currently not approved as a therapy for previously untreated Hodgkin lymphoma in Europe. “For a large number of previously untreated Hodgkin lymphoma patients diagnosed with Stage IV disease, progression will occur with current treatments, highlighting a true unmet need in this population,” said Anna Sureda, M.D., Ph.D., Head of the Hematology Department and Hematopoietic Stem Cell Transplant Programme, Institut Català d'Oncologia - Hospital Duran i Reynals. “In the ECHELON-1 cl

Diamond CBD, POTN Subsidiary, Enters the $46 Billion Coffee Market With the Release of Premium Line of CBD-Infused Coffee & Tea K-Kup Capsules14.12.2018 15:42Pressemelding

Diamond CBD Inc., wholly owned subsidiary of PotNetwork Holdings, Inc. (OTC Pink: POTN), a leader in hemp extraction and innovative CBD products for the wellness market, enters the Coffee segment, an industry expected to reach revenues of $46 Billion in 2018. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181214005308/en/ Experience a cup of Chill (Photo: Business Wire) Produced in accordance with a universal K-Cup design, these pods fit in almost all modern single cup coffee makers, making it an easily integrated enhancement to any environment, delivering 25mgs of CBD in a tasty favorite beverage at less than $5 per cup. This new line of premium Chill Coffee Capsules was recently added to the Company’s broad range of cannabinoid and natural hemp products. Each box comes with 4 individual capsules in original chill coffee, decaf chill coffee, chill black tea, and chill green tea flavors. The unit price for each box is $10.00

Henley & Partners Enlarges Executive Committee to Manage Expansion and Growth14.12.2018 14:00Pressemelding

Residence- and citizenship-by-investment programs have firmly established themselves over the past few years as the new frontier in terms of freedom, flexibility, and future-readiness, both for the countries issuing these programs and for the individual investors participating in them. The societal and economic value these programs generate is undisputed. The investment migration industry as a whole is currently grossing roughly USD 18 billion per year, with an expectation that it will hit the USD 20 billion mark very soon. Foreign direct investment (FDI) is now considered the lifeblood of economic growth for many developing and recovering smaller countries around the world. As such, the number of investment migration programs has been increasing rapidly, from just a handful of programs in the 1980s and 1990s to over 100 countries that now have investment migration provisions in their laws. There are more than 60 active programs today, with Moldova and Montenegro — both fast-growing Eu

Vargatef® plus docetaxel could be an option after failure of immunotherapy in lung cancer14.12.2018 09:07Pressemelding

Boehringer Ingelheim announced today the first interim results of VARGADO, an ongoing non-interventional study in routine clinical practice in Germany evaluating the efficacy and safety of Vargatef® (nintedanib) and docetaxel in patients with stage III/IV locally advanced or metastatic non-small cell lung cancer (NSCLC) of adenocarcinoma histology. The study consists of three cohorts, two of which allow for prior treatment with immune checkpoint inhibitors (ICIs) either in combination with chemotherapy in the first-line or as monotherapy in the second-line of treatment. The interim results from Cohort B (first-line chemotherapy, second-line immune checkpoint inhibitors, third-line Vargatef® plus docetaxel) were presented today at ESMO Immuno-Oncology Congress 2018 in Geneva.1 Despite a limited sample size, the VARGADO study adds to the body of evidence for nintedanib in lung adenocarcinoma following pre-treatment with chemotherapy and ICIs.1,3 The addition of nintedanib to docetaxel ha